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Background: Inflammatory bowel disease (IBD) is associated with high costs to society. Few data
on the impact of IBD on work disability and potential predictive factors are available.
Aim: To assess the prevalence of and predictive factors for work disability in Crohn's disease
(CD) and ulcerative colitis (UC).
Methods: A web-based questionnaire was sent out in seven university hospitals and seven
general hospitals in the Netherlands. Initially, 3050 adult IBD patients were included in this
prospective, nationwide cohort study, whereof 2629 patients were within the working-age (18–
64 years). We used the baseline questionnaire to assess the prevalence rates of work disability in
CD and UC patients within working-age. Prevalence rates were compared with the Dutch
background population using age- and sex-matched data obtained from Statistics Netherlands.
Multivariable logistic regression analyses were performed to identify independent demographic-
and disease-specific risk factors for work disability.
Results: In CD, 18.3% of patients was fully disabled and 8.8% partially disabled, compared to 9.5%
and 5.4% in UC patients (p b 0.01), respectively. Compared to Dutch controls, the prevalence was
significantly higher, especially in CD patients. Higher age, low education, depression, chronic back
pain, joint manifestations and typical disease-related risk factors such as penetrating disease
course and surgery in the past were all found to be associated with work disability.
Conclusion: We report high work disability rates in a large sample of IBD patients in the
Netherlands. CD patients suffer more frequently from work disability than UC patients. A
combination of demographic and disease-related factors is predictive of work disability.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.1. Introduction
Inflammatory bowel diseases (IBD) are chronic intestinal
disorders, comprising Crohn's disease (CD) and ulcerative colitis
(UC). IBD affects 2.5–3 million people in Europe, many of
whom develop disease as working-age adults.1 An important
consequence is therefore a reduced ability to work, which
can be decisive for future life expectations for patients
themselves.2–10 Work disability is associated with high costs
to society.7,9,11–13 The prevention or postponement of work
disability should therefore be an important goal in the
treatment of IBD patients.
The disability rates in previous reported studies vary
considerably and range between 15 and 25% in CD and 5–13%
in UC.2–9,12 This is undoubtedly related to different patient
populations, geographical differences and employed tools
for the measurement of disability. Over the last decade,
treatment goals of IBD have evolved from the induction and
maintenance of clinical remission to the prevention of
structural damage and long-term (work) disability with
expanding use and early introduction of anti-tumour necrosis
(anti-TNF) therapy and immunomodulators. Aggressive strate-
gies seem to result in a substantially improved quality-of-life,14
a reduction of hospitalisation and surgery,15,16 and might
benefit work productivity.17,18 Knowledge on predictive factors
for work disability could improve prevention strategies,increase quality-of-life and reduce future productivity
losses.
To date, few studies have attempted to explore the
predictive factors for work disability in IBD. Most of these
were underpowered,2,6 or were conducted in highly selected
populations.5,8 In the present study we aimed to 1) assess
the prevalence of work disability rate in a large nationwide
cohort of IBD patients, 2) compare the disability rates with
the general Dutch population and 3) determine predictive
factors for work disability.2. Materials and methods
2.1. Study design
BetweenOctober 2010 andOctober 2011we invited by letter all
identified IBD patients aged 18 years or older from seven
university hospitals and seven general hospitals (n = 9550) to
participate in the COIN study. Identification was based on the
Diagnosis Treatment Combinations (DTCs). We designed a
secure web-based questionnaire and participants were invited
to enter a username and password-secured and firewall-
protected website to fill-out questionnaires. All patients
were followed-up for 2 years at 3 month intervals. In total,
3050 patients were initially included in this cohort. Here,
592 M.E. van der Valk et al.we report on the results from the baseline questionnaire.
For the current analysis, we only included patients within
working-age, i.e. adults between 18 and 64 years. The
cohort organisation, patient diagnostic criteria, the repre-
sentativeness and validity (including a non-responder study)
of the study cohort have been described in detail
elsewhere.13
2.2. Outcome measure: work disability and predic-
tive factors
We used the same definition for work disability as employed
by the Dutch social security system.19 The self-reported
work disability is from ‘all causes’ and not exclusively
attributable to IBD. There are two types of disability
benefits; the first is for patients who are declared to be
fully (N80%) disabled after assessment. These patients are
entitled to an income-replacing disability benefit. The
second type of benefit is for patients who are declared to
be more than 35% disabled, but not fully and permanently
after assessment. These partially disabled patients are
entitled an income supplement benefit if their disability
forces them to switch to a less-well paid job. To compare the
work disability rates of the IBD patients with the Dutch
background population, we retrieved data on age- and
sex-matched work disability rates of the Dutch population
from Statistics Netherlands.20 Reference data from the
Dutch population were from 2011. We compared disability
by sex, by age groups, and separately for university hospitals
and general hospitals. We used the International Classifica-
tion of Functioning Disability and Health (ICF) to explain
work disability and to classify possible predictive factors for
work disability.21 Fig. 1 clarifies the classification and
classified all variables from the baseline questionnaire intoFigure 1 Work disability according to the International
Classification of Functioning, Disability and Health (ICF).17demographic factors, disease related factors, impaired body
function and structures, and external modifiers.
2.3. Statistical considerations
We analysed our data using SPSS version 18.0. We used
descriptive statistics to characterize patients with CD and UC.
Differences among groups were assessed by Student t-test
for continuous variables and χ2 for dichotomous variables,
Fisher's exact test was used where appropriate. To compare
the prevalence of work disability in our study cohort with the
Dutch background population, we used the Student t-test. In
order to determine factors associated with work disability, we
performed univariable logistic regression analysis with demo-
graphic and disease characteristics. Demographic and disease
specific characteristics that were associated (p b 0.10) with
chronic disability following univariable analysis were included
in the multivariable logistic regression analyses to identify
independent risk factors for work disability.
2.4. Ethical statement
The study was centrally approved by the medical ethics
committee of the University Medical Center Utrecht.3. Results
3.1. Patient population
Fig. 2 shows the study flowchart. In total, 2282 patients were
within working-age, of whom 1373 were with CD and 909 with
UC. Table 1 presents the demographics and disease character-
istics of the CD and UC population between 18 and 64 years old.
There were more females in the CD group than in the UC group
(65.7% and 56.2%, respectively). The mean ages of CD and UC
patients were 44.1 (SD 11.8) and 46.1 (SD 11.4) years. Of all CD
patients, 906 (66.0%) were cared for in university hospitals
versus 510 (56.1%) of all UC patients. The remaining patients
were treated in general hospitals. In total, 724 (52.7%) CD
patients reported a penetrating disease course. Of all CD
patients, 734 (53.5%) underwent abdominal surgery previously,
as compared to 164 (18.0%) in UC patients. Of the CD patients,
457 (33.3%) received biological therapy in the past as compared
to 87 (9.6%) of the UC patients Table 1.
3.2. Prevalence of work disability
In total, 728 (53.0%) CD and 605 (66.6%) UC patients were
currently employed (p b 0.01). In the CD group, 251 (18.3%)
patients were fully disabled as compared to 86 (9.5%) of the UC
patients (p b 0.01). Partial disability was encountered in 121
(8.8%) of CD patients and 49 (5.4%) of UC patients (p b 0.01).
Among partially disabled patients, the mean work hours per
week were 20 (SD 10) in CD patients and 22 (SD 9) in UC
patients. This was significantly lower as compared to fully
employed CD and UC patients, 32 (SD 10) and 33 (SD 9) hours
per week respectively (p b 0.01), which is in line with the
average work hours/week (32 h/week) for the Dutch back-
ground population aged 15 to 64 years.16
Table 1 Demographic and disease characteristics of study
population within the labour force (18–65 years).
CD UC
n = 1.373 n = 909
Male sex (%) 471 (34.3) 416 (45.8)
Age — years (±SD) 44.1 (11.8) 46.1
(11.4)
Smoking (%)
Current 307 (22.4) 86 (9.5)
Never 691 (50.3) 533 (58.6)
Ex smoker 375 (27.3) 290 (31.9)
Education (%)
Low education 868 (65.2) 519 (57.1)
Age at diagnosis — years (±SD) 27.8 (10.7) 32.0
(11.6)
Disease duration — median (IQR) 16.4 (10.8) 14.1 (9.9)
Disease localization (%)
Large bowel 379 (27.6) 909 (100)
Small bowel 261 (19.0) n.a.
Both small and large bowel 691 (50.3) n.a.
Unknown 42 (3.1) n.a.
Penetrating disease (%) 724 (52.7) n.a.
Disease in remission (%) 1166 (85.0) 759 (83.5)
Stoma (%) 161 (11.7) 51 (5.6)
Pouch (%) 22 (1.6) 86 (9.5)
Abdominal surgery (%) 734 (53.5) 164 (18.0)
Medication use — ever (%)
5-ASA 986 (71.8) 745 (82.0)
Corticosteroids 1063 (77.4) 551 (60.6)
Immunomodulators 865 (63) 327 (36.0)
Biological therapy 457 (33.3) 87 (9.6)
Joint complaints (%) 301 (21.9) 158 (17.4)
Chronic back pain (%) 143 (10.4) 86 (9.5)
Depression (%) 141 (10.3) 90 (9.9)
Ùniversity medical centre — now
(%)
906 (66) 510 (56.1)
Figure 2 Study flowchart.
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population
Fig. 3.A and B shows work disability in CD, UC and the Dutch
general population, stratified by age and sex. Overall work
disability rates were significantly higher in both female and
male CD patients than in the Dutch general population
(p b 0.01). The highest prevalence rates were found among
female CD patients. Unlike CD patients, UC patients treated
in general hospitals did not have higher work disability rates
than age- and sex-matched controls, whereas UC patients
treated in university hospitals did have higher work disability
rates than age- and sex-matched controls.
3.4. Predictive factors of work disability
Non-adjusted and adjusted odds ratios for work disability
in CD and UC are presented in Tables 2 and 3, respectively.
In both UC and CD higher age and lower education were
associated with work disability. Females with CD, but not UC
were prone to disability as well. Impaired body function (i.e.
self-reported disease activity) and structural body functions(i.e. penetrating disease course and surgery in the past)
were associated with work disability in CD. In UC patients,
only abdominal surgery in the past was an independent
predictor for work disability. Additional external modifiers
such as co-morbidities (joint manifestations, chronic back
pain and depression) were strong risk factors in both groups.
Previous use of corticosteroids was an independent predictor
for work disability in UC, while medication use in CD patients
was not a significant predictive factor.
4. Discussion
In this large, nationwide study, we report high work disability
rates in patients with IBD. The overall proportion of individuals
with CD or UC with full work disability was 18.3% and 9.5%,
respectively. Compared to the general Dutch population, the
work disability rates were the highest among CD patients,
especially those treated in university medical centres. UC
patients cared for in general hospitals did not differ from the
general Dutch population with respect to reported work
disability.
Rates of IBD-related work disability in literature range
widely between 5% and 25%.2–9 The two largest studies to
date reported high disability rates in line with our data,4,5
although the former included IBD patients of younger age
with a relative short disease duration of 7 years (SD 3), and
the latter studied a highly selected group with CD patients
with moderate to severe disease activity enrolled in a
clinical trial. Lower disability rates of 15% in CD patients and
5% in UC patients have been reported by Bernklev et al.3
These results were based on data, generated from 5 year
follow-up visits of newly diagnosed patients. Comparison of
work disability rates between different countries is ham-
pered by differences in socioeconomic and political factors.
Figure 3 Work disability in patients aged between 18 and 65 years with Crohn's Disease (CD) and ulcerative colitis (UC) compared to
the general population in the Netherlands.
594 M.E. van der Valk et al.We found higher disability rates in our IBD cohort as
compared to the Dutch general population, in line with a
previously published Dutch population-based study.4 A Norwe-
gian inception cohort study, however, found higher disability
rates for patients with CD, but not for patients with UC.3 An
explanation for this discrepancy could be the high prevalence
of work disability among the general Norwegian population,
being 8.8% (as compared to 6.6% in Dutch controls).
The large size of our cohort of IBD patients enabled us to
study a large panel of possible predictive factors for work
disability. In order to explain work disability as a multifac-
torial problem, we classified predictive variables according
to the International Classification of Functioning Disability
and Health into demographic factors, IBD-related factors,
impaired body function or structural damage, and external
modifiers. We found that in patients with CD, demographic
factors such as female gender, increasing age and low
education are associated with work disability. The analysis
of patients with UC offered a similar picture, except that
female gender was not found to be a predictive factor. We
did not find consistent evidence that disease duration
predicted work disability. It is possible that disease activity
hampers work disability most profoundly in early disease,
whereas structural damage and IBD-related complications
may become more important in long-term disease.Most of the factors related to impaired body functions or
body structures were associated with increased risk of work
disability. We found abdominal surgery in the past to be an
independent predictor for work disability in both CD and UC.
This has been reported in previous studies as well, with a 1.6
to 7.1 time higher risk for work disability.2,4,5 Furthermore,
we found an association between penetrating disease course
and work disability. Previous studies showed a comparable
cumulative risk of perianal involvement in CD of 50%, which
is in line with our findings.22,23 One potential explanation
for the increased risk of work disability is the poor prognosis
of CD patients with fistulas. Perianal fistulas are associated
with high morbidity, local pain and discomfort, frequent
surgical drainage with associated risks of complications,
and therefore have a negative impact on quality of life and
subsequently work productivity.22,23 These findings un-
derscore the importance of preventing structural damage.
Whether this can be achieved by adopting an accelerated
step-up or early top-down approach remains to be
proven.24,25
In multivariate analysis, CD patients with joint complaints
have a 2.6-fold increased risk of work disability as compared to
a 2.3-fold increased risk in UC patients. Thesemusculoskeletal
disorders are known to be a primary cause of disability in the
general working population. Joint manifestations are reported
Table 2 Univariate and multivariate analysis of factors associated with work disability in employed or disabled Crohn's disease






Unadj. OR (95% CI) Adj. OR (95% CI)
Demographic factors
Female sex (%) 258 (69.4) 285 (39.1) 1.46 (1.12–1.89) 1.55 (1.13–2.13)
Age — years (%)
b40 84 (22.6) 326 (44.8) 1.00 1.00
40–55 171 (46.0) 304 (41.8) 2.18 (1.61–2.96) 1.48 (1.01–2.19)
N55 117 (31.5) 98 (13.5) 4.87 (3.42–6.94) 3.44 (2.15–5.51)
Low education (%) 301 (78.6) 381 (52.0) 3.38 (2.55–4.49) 2.63 (1.90–3.65)
Disease related factors
Age at diagnosis — years (%)
b16 35 (9.1) 64 (8.7) 1.00 –
16–40 279 (72.8) 568 (77.6) 0.90 (0.58–1.39)
N40 69 (18.0) 100 (13.7) 1.26 (0.76–2.11)
Disease duration — years (%)
b10 71 (18.8) 290 (39.8) 1.00 1.00
10–20 130 (34.9) 235 (32.2) 2.32 (1.66–3.24) 1.37 (0.92–2.04)
N20 172 (46.2) 203 (27.9) 3.61 (2.60–5.01) 1.52 (0.97–2.37)
Body function and structures
Self reported flare (%) 80 (21.5) 89 (12.2) 1.94 (1.39–2.70) 1.60 (1.07–2.39)
Penetrating disease (%) 242 (65.1) 347 (47.7) 2.11 (1.63–2.73) 1.47 (0.94–2.30)
Stoma (%) 71 (19.1) 60 (8.2) 2.77 (1.93–3.99) 1.55 (1.13–2.13)
Pouch (%) 7 (1.9) 12 (1.6) 1.18 (0.49–2.87) –
Abdominal surgery (%) 262 (70.4) 344 (47.3) 2.65 (2.04–3.44) 1.57 (1.12–2.19)
External modifiers
Medication use — ever (%)
5-ASA 283 (76.1) 513 (70.5) 1.30 (0.98–1.72) –
Corticosteroids 318 (85.5) 541 (74.3) 1.95 (1.41–2.70) 1.37 (0.90–2.09)
Immunomodulators 259 (69.6) 445 (61.1) 1.46 (1.12–1.90) 1.09 (0.75–1.58)
Biological therapy 156 (41.9) 215 (29.5) 1.69 (1.30–2.19) 1.40 (0.99–1.97)
Joint complaints (%) 147 (39.5) 94 (12.9) 4.41 (3.28–5.94) 2.60 (1.84–3.69)
Chronic back pain (%) 76 (20.4) 728 (6.5) 3.85 (2.62–5.65) 2.47 (1.55–3.94)
Depression (%) 62 (16.7) 47 (6.5) 2.82 (1.88–4.21) 1.92 (1.19–3.10)
University medical centre (%) 279 (75.0) 447 (61.4) 1.87 (1.42–2.47) 1.68 (1.21–2.35)
Smoking (%)
Never 141 (37.9) 401 (55.1) 1.00 1.00
Current 104 (28.0) 141 (19.4) 2.08 (1.51–2.85) 1.34 (0.91–1.96)
Ex-smoker 127 (34.1) 186 (25.5) 1.98 (1.48–2.65) 1.36 (0.96–1.93)
595Risk factors of work disability in patients with inflammatory bowel disease — A Dutch nationwide web-based surveyin 16 to 33% of all IBD patients, which is in line with the rates
found in our study.26 Furthermore, axial arthropathies are
common in IBD and can result in chronic back pain.27 Almost
10% of our study population reported chronic back pain (IBD
related or non-IBD related) which was associated with a
2.5-fold increased risk of work disability in CD patients and
2.7-fold increased risk in UC patients.
To our knowledge, this is the largest study to date,
examining the prevalence and risk factors for work disability
in IBD patients. The inclusion of patient from both university
and general hospitals throughout the Netherlands ascertained
a good case mix. In order to enrol a large number of patients,
we opted for the present web-based design. An inherent
limitation of such a strategy is sampling bias. We assessed therepresentativeness of our study by performing a non-responder
study. Significant differences in demographic and disease
characteristics between responders and non-responders
were not identified.13 In addition, data on disease charac-
teristics and employment status were self-reported, possi-
bly introducing bias as well. Yet, previous studies showed
that the accuracy of responses to health-related question-
naires from patients with IBD is as high as 95%.28
In an era of increasing financial pressure on every stake-
holder in the society, it is imperative to maximize the value of
healthcare costs by also demonstrating a return on investment
through improvement in work productivity. Collaboration of
medical specialists and occupation physicians might prevent
future work disability or job loss and decrease prevalent work






Unadj. OR (95% CI) Adj. OR (95% CI)
Demographic factors
Female sex (%) 69 (51.1) 306 (50.6) 0.97 (0.67–1.39) 1.08 (0.70–1.66)
Age — years (%)
b40 23 (17.0) 203 (33.6) 1.00 1.00
40–55 59 (43.7) 281 (46.4) 1.85 (1.11–3.10) 1.41 (0.78–2.53)
N55 53 (39.3) 121 (20.0) 4.41 (2.60–7.50) 4.31 (2.24–8.30)
Low education (%) 99 (69.2) 304 (50.2) 2.24 (1.52–3.30) 1.77 (1.14–2.76)
Disease related factors
Age at diagnosis — years (%)
b16 10 (7.0) 36 (6.0) 1.00 –
16–40 84 (58.7) 436 (72.1) 0.69 (0.33–1.45)
N40 49 (34.3) 133 (22.0) 1.33 (0.61–2.87)
Disease duration — years (%)
b10 34 (25.2) 269 (44.5) 1.00 1.00
10–20 55 (40.7) 183 (30.2) 2.35 (1.50–3.70) 1.85 (1.11–3.06)
N20 46 (34.1) 153 (25.3) 2.24 (1.40–3.60) 1.02 (0.58–1.80)
Body function and structures
Self reported flare (%) 21 (15.6) 103 (17.0) 0.89 (0.54–1.47) –
Stoma (%) 14 (10.4) 26 (4.3) 2.81 (1.47–5.39) 1.03 (0.45–2.33)
Pouch (%) 24 (17.8) 49 (8.1) 2.53 (1.51–4.23) 0.92 (0.45–1.88)
Abdominal surgery (%) 262 (70.4) 344 (47.3) 3.71 (2.46–5.60) 3.62 (2.01–6.52)
External modifiers
Medication use — ever (%)
5-ASA 109 (80.7) 501 (82.8) 0.89 (0.56–1.42) –
Corticosteroids 100 (74.1) 349 (57.7) 2.26 (1.49–3.41) 2.43 (1.49–3.96)
Immunomodulators 51 (37.8) 210 (34.7) 1.17 (0.80–1.70) –
Biological therapy 15 (11.1) 53 (8.8) 1.22 (0.67–2.24) –
Joint complaints 45 (33.3) 71 (11.7) 4.05 (2.65–6.19) 2.27 (1.36–3.78)
Chronic back pain 23 (17.0) 42 (6.9) 2.71 (1.58–4.64) 2.51 (1.31–4.83)
Depression 27 (20.0) 45 (7.4) 3.04 (1.82–5.07) 2.25 (1.23–4.11)
University medical centre (%) 97 (71.9) 326 (53.9) 2.00 (1.35–2.30) 1.37 (0.86–2.16)
Smoking (%)
Never 72 (53.3) 359 (59.3) 1.00 1.00
Current 20 (14.8) 57 (9.4) 1.77 (1.01–3.09) 1.32 (0.68–2.55)
Ex-smoker 43 (31.9) 189 (31.2) 1.19 (0.80–1.79) 0.81 (0.51–1.30)
596 M.E. van der Valk et al.disability. This study shows that disease activity, and structural
damage due to surgery and penetrating disease are associated
with loss of productivity. We need long-term prospective
studies to determine whether or not improving the man-
agement of IBD will result in preventing structural damage,
improvements in work productivity and a reduction in the
economic burden of the disease.Author contribution
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